Importantly, reductions in TNF-α independently predicted CAP improvement, emphasizing the pivotal role of chronic inflammation in MASLD pathophysiology and its responsiveness to dietary intervention. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.